May 10, 2022
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
| Attn: | Daniel Crawford |
| Celeste Murphy |
| Re: | OKYO Pharma LTD (the “Company”) | ||
| Registration Statement on Form F-1/A | |||
| File No. 333-263326 | |||
| Acceleration Request | |||
| Requested Date: May 12, 2022 | |||
| Requested Time: 5:00 p.m., Eastern Daylight Time | |||
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), ThinkEquity LLC, as representative of the several underwriters, hereby joins the Company in requesting that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form F-1/A (File No. 333-263326) (the “Registration Statement”) to become effective on Thursday, May 12, 2022, at 5:00 p.m., Eastern Daylight Time, or as soon as practicable thereafter.
Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.
[Signature Page Follows]
| -1- |
Securities and Exchange Commission, p. 2
May 10, 2022
| Very truly yours, | ||
| ThinkEquity LLC | ||
| By: | /s/ Priyanka Mahajan | |
| Name: | Priyanka Mahajan | |
| Title: | Managing Director, Investment Banking | |
| cc: | Gary Jacob, OKYO Pharma Ltd |
| Jeffrey Fessler, Sheppard, Mullin, Richter & Hampton LLP | |
| Anthony Marsico, Dorsey & Whitney LLP |
| -2- |
